Differentiation of Pluripotent Stem Cells to Functional Cardiac Progenitor Cells for Treatment of Injured Heart
PATENT STATUS
PCT application disclosing this invention was filed in June 2018.
OVERVIEW OF TECHNOLOGY ON OFFER
A method of differentiating pluripotent stem cells to cardiomyocyte progenitor cells for use in regenerative cardiology. This technology also identifies functional cardiomyocyte progenitor cells for their use in repairing injured heart.
BRIEF DESCRIPTION
Regeneration of injured human heart muscle is an unmet clinical need. Current available approaches, such as adult bone marrow injections into the infarct region, have had limited success. There is a need to develop clinical-quality cells that can form new functional cardiac muscle in vivo.
Dr. Tryggvason’s lab at Duke-NUS Medical School has developed a novel method for generating cardiomyocyte progenitors from pluripotent stem cells, using laminin substrates. This chemically-defined and xeno-free method allows for a controllable and highly reproducible generation of cardiomyocyte progenitors for various applications including regenerative cardiology and testing for drug effects and cardiotoxicity. This technology also allows identification of functional cardiomyocyte progenitor cells to be used in treatment. After identification, the functional cardiomyocyte progenitor cell or cell population can be separated from non-functional cells. These cells can then be used for implantation and treatment purposes.
POTENTIAL APPLICATIONS
Treatment of injured heart and regeneration of damaged heart muscle using cardiomyocyte progenitor cells.
PUBLICATIONS
In Vivo Generation of Post-infarct Human Cardiac Muscle by Laminin-Promoted Cardiovascular Progenitors
INVENTOR BIO
Karl Tryggvason
CONTACT
Please email us for further enquiries: cted@duke-nus.edu.sg